Today: 11 June 2026
Browse Category

NYSE:JNJ 7 February 2026 - 6 June 2026

Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

Johnson & Johnson jumped 2.02% to $232.77 Friday—outperforming a plunging S&P 500—after a Los Angeles jury found the company not negligent in a talc cancer lawsuit; investors now eye next week’s Goldman Sachs healthcare conference and a fresh $1.34 dividend, as J&J touts new drug launches and raised its 2026 outlook despite ongoing litigation and Stelara sales declines.
6 June 2026
·
Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson shares fell 1.77% to $226.71 Friday amid a broad market selloff but ended the week up about 2.4%. The NYSE is closed for the weekend, with trading set to resume Monday. Investors are watching upcoming neuropsychiatry data presentations and the global launch of the Shockwave C2 Aero Coronary IVL Catheter. No new earnings report is expected next week.
16 May 2026
·
Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

The Dow rose 100.62 points to 49,268.41 on Tuesday, lifted by gains in Coca-Cola and Johnson & Johnson, while the S&P 500 fell 0.64% and the Nasdaq dropped 1.24% as investors sold AI-linked shares. Coca-Cola reported Q1 net revenue up 12% and raised its full-year earnings forecast. Nvidia, AMD, and Arm all declined sharply. Brent crude hovered near $111 amid U.S.-Iran tensions and OPEC uncertainty.
28 April 2026
·······
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson reported first-quarter revenue of $24.1 billion, up 9.9%, and adjusted earnings of $2.70 per share, both above analyst estimates. Sales of cancer drug Darzalex hit $4 billion, while Stelara fell 60% to $656 million. The company raised its 2026 outlook, nudging full-year sales guidance to $100.8 billion. J&J shares slipped 0.27% to $237.96 in early trading.
14 April 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson shares fell 0.7% to $245.07 Wednesday after its lupus drug nipocalimab received FDA Fast Track status. The stock lagged a broader market rally, with the S&P 500 ETF up nearly 1%. Investors weighed pipeline progress against ongoing legal risks and recent defensive trading. Johnson & Johnson will present at the Barclays Global Healthcare Conference on March 10.
4 March 2026
··
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson shares fell 0.6% to $238.64 in after-hours trading Monday as healthcare stocks lagged, despite gains in the broader market. The company will present at the Barclays Global Healthcare Conference on March 10. J&J faces over 67,500 talc lawsuits, with a New Jersey court last week disqualifying a plaintiffs’ firm. The board declared a $1.30 quarterly dividend, with the stock going ex-dividend Feb. 24.
10 February 2026
·
Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

A New Jersey appeals court disqualified Beasley Allen from representing plaintiffs in consolidated state talc cases against Johnson & Johnson; the firm plans to appeal. J&J shares closed up 0.93% at $239.99, near a 52-week high, before slipping slightly after hours. The company also reported positive pilot data for its investigational AFib platform.
8 February 2026
··
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
7 February 2026
··
1 2 3 … 9

Stock Market Today

  • FireFly Metals (ASX:FFM) Faces Valuation Questions After Mixed Price Moves
    June 11, 2026, 1:19 AM EDT. FireFly Metals (ASX:FFM) shares dropped 5.2% in one day and 20.4% over the past week, contrasting with a strong 77.9% total return over the past year. The stock trades at 2.8 times price-to-book (P/B), above the Australian metals and mining industry average of 1.8, suggesting investors assign a premium for future growth despite no current revenue and A$6.359 million losses. Analysts question if this premium reflects genuine opportunity or risk related to funding and exploration outcomes at FireFly's Green Bay project. A discounted cash flow (DCF) model estimates intrinsic value far above the current A$1.82 price, highlighting valuation discrepancies and market uncertainty around this copper explorer.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Go toTop